Form 4: Vivani Medical CFO Granted 600,000 Stock Options in Executive Compensation Move

Vivani Medical, Inc.'s Chief Financial Officer, Anthony Baldor, was granted 600,000 stock options with a 10-year term and a vesting schedule tied to continued service.

Summary

• Anthony Baldor, Chief Financial Officer of Vivani Medical, Inc. (VANI), was granted 600,000 stock options.
• The options have an exercise price of $1.15 per share.
• The grant date for these options was June 15, 2025.
• The options have a 10-year term, expiring on June 14, 2035.
• Vesting for the options begins with 25% vesting after one year, followed by monthly vesting over the subsequent 36 months, contingent on Mr. Baldor's continued service.

Sentiment

Score: 6

Explanation: The document reports a standard executive compensation event (stock option grant), which is generally a neutral to slightly positive signal as it aligns management incentives with shareholder interests, but does not contain information that would significantly alter a company's financial outlook.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's interests with those of shareholders, incentivizing long-term performance.
• The 10-year term provides a significant window for the options to become in-the-money, reflecting a long-term commitment to the company's success.

Risks

• The value of the stock options is directly tied to the future performance of Vivani Medical, Inc.'s stock price, meaning they could become worthless if the stock price does not exceed the exercise price.
• The vesting schedule is contingent on the CFO's continued service, meaning unvested options would be forfeited upon departure from the company.

Future Outlook

The stock options granted to the Chief Financial Officer are designed to vest over a period of four years (25% after one year, then monthly for 36 months), contingent on continued service, indicating a long-term incentive structure for executive retention and performance.

Industry Context

The granting of stock options to key executives like the Chief Financial Officer is a standard practice across various industries, particularly in the biotechnology and medical device sectors, to attract, retain, and incentivize talent by aligning their financial interests with the company's long-term success and shareholder value creation.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased shareholder value due to aligned management incentives.
• Employees: Reflects standard executive compensation practices, potentially setting a precedent for other key personnel.

Next Steps

• The stock options will begin vesting 25% after one year from the grant date (June 15, 2025).
• Subsequent vesting will occur monthly for 36 months thereafter, subject to continued service.

Key Dates

Keywords

Vivani Medical, VANI, Stock Options, SEC Form 4, Executive Compensation, Chief Financial Officer, Anthony Baldor, Equity Grant, Insider Transaction